Olmefast
Generic Name
Olmesartan medoxomil
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olmefast 10 mg tablet | ৳ 5.00 | ৳ 50.00 |
Description
Overview of the medicine
Olmefast 10 mg Tablet contains Olmesartan medoxomil, an Angiotensin II Receptor Blocker (ARB), used to treat high blood pressure (hypertension) in adults. It helps to lower blood pressure, which can prevent strokes, heart attacks, and kidney problems.
Uses & Indications
Dosage
Adults
The usual starting dose is 20 mg once daily. For patients requiring further blood pressure reduction, the dose can be increased to 40 mg once daily. Doses above 40 mg do not appear to have greater effect. For Olmefast 10 mg, it is usually used for initial therapy or for patients requiring a lower dose.
Elderly
No initial dosage adjustment is generally required for elderly patients (≥65 years) unless there is severe renal impairment. Monitor renal function.
Renal_impairment
No initial dosage adjustment is recommended for patients with mild to moderate renal impairment. For patients with severe renal impairment (creatinine clearance <20 mL/min), a starting dose of 10 mg once daily is recommended, and the dose should not exceed 20 mg once daily.
How to Take
Take Olmefast 10 mg Tablet orally once daily, with or without food, as directed by your doctor. Swallow the tablet whole with water; do not crush, chew, or break it.
Mechanism of Action
Olmesartan medoxomil is a prodrug that is rapidly converted to its active metabolite, olmesartan. Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor in various tissues, including vascular smooth muscle and the adrenal gland. This blockade inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation, reduced systemic vascular resistance, and consequently, a reduction in blood pressure.
Pharmacokinetics
Onset
Antihypertensive effect generally achieved within 2 weeks, with maximum reduction after 8 weeks.
Excretion
Excreted renally (35-50%) and hepatobiliary (50-65%) as unchanged drug.
Half life
Approximately 13 hours.
Absorption
Rapidly absorbed from the gastrointestinal tract and converted to olmesartan. Absolute bioavailability is approximately 26%. Peak plasma concentrations of olmesartan are reached within 1-2 hours after an oral dose.
Metabolism
Minimal hepatic metabolism. No significant metabolism by cytochrome P450 enzymes.
Side Effects
Contraindications
- •Hypersensitivity to olmesartan medoxomil or any component of the formulation.
- •Pregnancy (second and third trimesters) due to risk of fetal injury.
- •Concomitant use with aliskiren in patients with diabetes.
- •Severe hepatic impairment.
Drug Interactions
Lithium
Increased serum lithium concentrations and lithium toxicity have been reported with concomitant use. Monitor serum lithium levels.
Aliskiren
Concomitant use with aliskiren is contraindicated in patients with diabetes due to increased risk of renal impairment, hyperkalemia, and hypotension.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
May reduce the antihypertensive effect of olmesartan and can increase the risk of renal impairment, especially in elderly, volume-depleted, or renally impaired patients. Monitor renal function.
Potassium-sparing diuretics, potassium supplements, or other potassium-containing drugs
May lead to increased serum potassium levels (hyperkalemia). Monitor serum potassium.
Storage
Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
The most likely manifestation of overdose would be hypotension and tachycardia; bradycardia could occur from parasympathetic stimulation. If symptomatic hypotension occurs, initiate supportive treatment.
Pregnancy & Lactation
Pregnancy: Contraindicated during the second and third trimesters due to fetal toxicity. Use of drugs affecting the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Lactation: It is not known whether olmesartan is excreted in human milk, but a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months
Availability
Available in pharmacies and hospitals
Approval Status
FDA Approved (for generic olmesartan)
Patent Status
Off-patent (for generic olmesartan)
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
